Climacteric Medicine - Where Do We Go?: Proceedings of the 4th Workshop of the International Menopause Society
Hermann P.G. Schneider, Frederick Naftolin
CRC Press, Sep 22, 2004 - Medical - 256 pages
At a time when ongoing research and clinical investigation into the use of HRT in perimenopausal women are incomplete--and when certain controversies remain unresolved--this summary of current opinion and knowledge fills the need for authoritative reference on this topic. Written by a 'Blue Ribbon' panel, the book addresses the wide range of advanc
What people are saying - Write a review
We haven't found any reviews in the usual places.
lack of Darwinian adaptation drives its physiology
2 A holistic approach to mature womens health and aging
3 Natural history of menopause studies and related efforts at the National Institute on Aging NIH
4 Major findings of the Melbourne Womens Midlife Health Project
5 The Womens Health in the Lund Area WHILA study
6 Adequately assessed quality of life
the Asian perspective
17 Specific products for individual therapy
18 Are all HRT preparations the same?
differences between hormone preparations?
effect of stage of menopause on outcomes
21 How representative are the results of the WHI for daily clinical decisions about hormone therapy in other regions of the world?
the validity of the epidemiological evidence
consequences for clinical practice
24 Do genes determine risk and benefits of hormone therapy?
8 Alternatives to hormone therapy in menopausal women
10 Recent clinical data and the role of menopausal hormone therapy today
11 Impact on current clinical practice in Spain
12 A clinicians response to the WHI
13 Pharmacology during the menopausal transition
14 Some background considerations relevant to the evaluation of the effects of hormone therapy
15 Menopausal medicine and its potential drug development opportunities
16 Clinical background of prescribing tibolone
new pharmacological and endocrinological approaches
26 Future perspectives in hormone replacement therapy and menopause research
current priorities future directions
28 Natural history and progress of the menopause
29 Recommendations for hormone therapy based on the Womens Health Initiative
30 What hormone preparations will be available?
31 Guidelines for the hormone treatment of women in the menopausal transition and beyond
activity alendronate associated atherosclerosis baseline benefits blood pressure body mass index bone density bone loss bone mineral density breast cancer breast cancer risk cardiovascular disease cells climacteric clinical trials cohort combined conjugated equine estrogens coronary heart disease decrease Dennerstein diabetes dose effects of estrogen endometrial Engl estradiol estrogen and progestin estrogen plus progestin estrogen receptor estrogen replacement estrogen therapy estrogen/progestin follow-up hip fracture hormone replacement therapy hot flushes increased risk levels menopausal symptoms menopausal transition menopausal women menstrual ment metabolic Million Women Study norethisterone observational studies Obstet Gynecol oral osteoporosis outcomes patients perimenopause placebo population postmeno progesterone progestin protein raloxifene randomized controlled trial reduced relative risk reported risk factors risk of breast SERMs serum significant statins steroid stroke tamoxifen testosterone tibolone tion tissue transdermal treatment vaginal vascular vasomotor symptoms vertebral fractures WHI study Women’s Health Initiative